IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

NCT01480986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Progression Free Survival of the Treatment

Interventions

DRUG: Irinotecan combined with cisplatin, octreotide lar

Sponsor

Peking University